Pulmatrix (NASDAQ:PULM) Now Covered by StockNews.com

Equities researchers at StockNews.com began coverage on shares of Pulmatrix (NASDAQ:PULM) in a research report issued to clients and investors on Wednesday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Pulmatrix Price Performance

Shares of NASDAQ:PULM opened at $6.22 on Wednesday. The firm’s 50 day simple moving average is $3.20 and its 200 day simple moving average is $2.45. Pulmatrix has a fifty-two week low of $1.55 and a fifty-two week high of $8.44. The company has a market capitalization of $22.70 million, a price-to-earnings ratio of -2.36 and a beta of 1.54.

Pulmatrix Company Profile

Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.